理解市场 | 加科思-B 盘中涨超 7% 公司出售非核心项目 聚焦肿瘤创新药核心管线
JACOBIO-B rose over 7% during the trading session, and as of the time of writing, it is up 6.12%, priced at HKD 7.8, with a transaction volume of HKD 23.9374 million. In terms of news, JACOBIO previously announced that it has signed a capital increase and equity transfer agreement with Haisong Capital and an industrial partner. According to this agreement, Haisong Capital will acquire 80% of the equity of JACOBIO's subsidiary, JACOREKANG, with an initial payment of RMB 125 million and a milestone payment of RMB 75 million. After completion, JACOBIO's stake in JACOREKANG will be reduced to 10%. The announcement stated that this transaction aligns with the group's strategic development focused on key pipeline products in oncology targeting different critical cellular pathways (including KRAS, MYC, P53, and tumor immunity), optimizing capital allocation, fully ensuring the development of core oncology pipeline projects, achieving strategic focus, enhancing organizational efficiency, while retaining future project value through a risk-sharing model. The consideration for the equity transfer (after deducting various taxes and fees) is intended to be used for the research and development, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects
According to Zhitong Finance APP, JACOBIO-B (01167) rose over 7% during the trading session, and as of the time of writing, it was up 6.12%, priced at HKD 7.8, with a transaction volume of HKD 23.9374 million.
In terms of news, JACOBIO previously announced that it had signed a capital increase and equity transfer agreement with Haisong Capital and an industrial partner. According to this agreement, Haisong Capital will acquire 80% of the equity of JACOBIO's subsidiary, JACOREKANG, with an initial payment of RMB 125 million and a milestone payment of RMB 75 million. After completion, JACOBIO's shareholding in JACOREKANG will be reduced to 10%.
The announcement stated that the transaction aligns with the group's strategic development focused on key pipeline products in oncology targeting different critical cell pathways (including KRAS, MYC, P53, and tumor immunity), optimizing capital allocation, fully ensuring the development of core oncology pipeline, achieving strategic focus, enhancing organizational efficiency, while retaining future project value through a risk-sharing model. The consideration for the equity transfer (after deducting various taxes and fees) is intended for the research and development, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects
